Aurobindo Pharma is currently trading above all its key moving averages, namely the 20-day, 50-day, 100-day and 200-day moving averages. More importantly, these averages are aligned in the desired sequence, which points to a favourable trend structure.
The moving average ribbon remains in an uptrend. On the weekly chart, Bollinger Bands are also trending higher, while on the daily chart, they are expanding, indicating a buildup in momentum. The relative strength line is rising and is close to an 11-month high, which shows improving outperformance.
The 14 period daily RSI is also in an uptrend and has rebounded after taking support near its 9 period average, reinforcing the positive bias. At the same time, the daily MACD remains in a strong uptrend and continues to diverge from its 9-period average, which further supports the constructive setup.
Recent Development In The US Market
In a recent business update, the company said that its subsidiary, Eugia Pharma Specialities Limited, has launched Pomalidomide Capsules in 1 mg, 2 mg, 3 mg and 4 mg strengths in the US market.
According to IQVIA MAT data for the 12 months ending January 2026, the US market size for Pomalidomide capsules is estimated at around $3.3 billion. Pomalidomide is a third-generation immunomodulatory drug used along with dexamethasone and, in some cases, bortezomib, for the treatment of relapsed or refractory multiple myeloma and AIDS-related Kaposi sarcoma.
Aurobindo Pharma Valuation Compared With Sun Pharma, Divi’s Lab, Cipla
From a valuation standpoint, Aurobindo Pharma appears to be trading near its three-year median price-to-earnings multiple of 20.7x, with the stock currently valued at around 20.78x earnings. This suggests that the stock is broadly in line with its own medium term historical valuation band rather than trading at a stretched premium.
When compared with large listed peers in the pharmaceutical space, Aurobindo Pharma stands at the lower end of the valuation spectrum. Sun Pharma trades at 35.85x, Divi’s Laboratories at 67.46x, Torrent Pharma at 64.95x and Cipla at 22.45x. Against this backdrop, Aurobindo Pharma’s valuation looks relatively lower than most major peers, while also remaining close to its own historical median.
Stock Name
| PE
|
Sun Pharma
| 35.85
|
Divi’s Laboratories
| 67.46
|
Torrent Pharma
| 64.95
|
Cipla
| 22.45
|
Aurobindo Pharma
| 20.78
|
Source: Screener
Conclusion
With the broader market sentiment improving, pharma stocks finding support, and Aurobindo Pharma nearing the upper end of a long-held trading range, the stock is drawing attention on both technical and business developments. The recent US launch by its subsidiary adds a fresh fundamental trigger, while its valuation remains relatively moderate compared with several large peers. Taken together, these factors make the stock one to watch as it approaches an important technical zone.
Also Read: GIFT Nifty Jumps 400 Points, Crude Oil Slips to $86